Merus Labs International has announced two key additions to its executive leadership team effective July 1, 2016, Dr. Michael Bumby as chief financial officer and Frank Fokkinga as Vice president, Global Regulatory Affairs, Quality and Compliance.

Bumby, as chief financial officer, succeed Andrew Patient. Patient will remain with Merus Labs for a period of time to ensure a smooth transition. Bumby was most recently the CFO of Acerus Pharmaceuticals. Bumby had a diverse 14 year career at Eli Lilly, including Corporate Finance & Investment Banking at Lilly's global headquarters in Indianapolis, leading international business development activities for early and late stage assets, and regional CFO for Lilly's Czech and Slovak subsidiaries based in Prague.

The company also appointed Fokkinga as vice president, Global Regulatory Affairs, Quality and Compliance. Based in Zurich, Switzerland, Fokkinga has over 30 years of pharmaceutical experience in regulatory affairs, global market research, business development and market access. Fokkinga has a proven history of success with gaining product approval and market access across Europe in a variety of therapeutic categories. Fokkinga previously served as vice president, International Regulatory Affairs at Takeda Pharmaceuticals. He also progressed a variety of leadership roles at Genzyme (now part of Sanofi) and Organon (now part of Merck). 

"The board of directors and I are delighted to welcome Dr. Bumby and Mr. Fokkinga to the Merus Labs executive leadership team," said Barry Fishman, chief executive officer. "Their enthusiasm, entrepreneurial spirit and expertise is expected to accelerate the execution of our growth strategy."

Merus Labs is a specialty pharmaceutical company focused on acquiring established products. The company leverages its expertise and commercial platform in Europe, Canada and select other markets to deliver value.